Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd (KMDA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products for rare and serious conditions. Its news flow reflects activity across commercial operations, clinical programs, plasma collection, and corporate strategy.
On this page, readers can follow Kamada news related to its proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Company announcements frequently discuss revenue trends, adjusted EBITDA, and guidance, highlighting the contribution of its Proprietary Products and Distribution segments, including biosimilar launches in Israel and supply agreements in markets such as Canada.
News items also cover clinical and post-marketing research, including updates on the InnovAATe Phase 3 trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency and its subsequent discontinuation following an interim futility analysis, as well as the SHIELD study evaluating CYTOGAM in high-risk kidney transplant recipients. Regulatory and operational milestones, such as FDA approval of the Houston, Texas plasma collection center and expansion of plasma collection capacity across Kamada’s three Texas sites, are recurring topics.
Investors and followers of KMDA stock can use this feed to track quarterly and annual financial results, guidance updates, tender awards like the Canadian Blood Services supply extension, and participation in healthcare and investor conferences. Regularly reviewing this page provides a consolidated view of Kamada’s commercial progress, R&D developments, and strategic initiatives as reported in its press releases and related filings.
Kamada (NASDAQ: KMDA) obtained an Israel Tax Authority ruling for its previously announced $0.25 per-share cash dividend (approximately $14.4 million), payable April 7, 2026 to shareholders of record March 23, 2026. The Company will withhold 25% initially; Treaty-state Nasdaq shareholders may apply for reduced withholding or exemption by May 9, 2026.
The Tax Agent is IBI Trust Management; full procedures, documentation requirements, and timing for refunds to eligible shareholders are specified in the Ruling.
Kamada (NASDAQ: KMDA) announced FDA approval of its plasma collection center in San Antonio, Texas, cleared to commence commercial sales of normal source plasma as of March 26, 2026.
The 11,100 sq ft facility supports up to 50 donor beds, has planned capacity of ~50,000 liters/year and is expected to generate $8 million to $10 million annually at full capacity. Kamada said it will seek subsequent EMA inspection/approval for the site.
Kamada (NASDAQ: KMDA) reported record 2025 results: $180.5M revenue (+12% YoY), $42.0M adjusted EBITDA (+23% YoY) and $20.2M net income (+40% YoY). The company generated $25.5M cash from operations and ended 2025 with $75.5M cash. Kamada affirmed 2026 guidance of $200M–$205M revenue and $50M–$53M adjusted EBITDA, adopted an annual cash dividend of $0.25 per share, and announced strategic focus on commercial expansion, plasma collection ramp-up and M&A.
Kamada (NASDAQ: KMDA) declared a cash dividend of $0.25 per share (approx. NIS 0.77), totaling about $14.4 million. The dividend is payable on April 6, 2026 to shareholders of record as of March 23, 2026.
The payment follows the Board's newly adopted annual cash dividend policy, under which the company intends to distribute at least 50% of annual net income, subject to Board discretion and applicable Israeli Companies Law tests. The company reported record revenue and profitability for full-year 2025 and will withhold tax under Israeli law; a tax ruling for non‑Israeli shareholders has been requested.
Kamada (NASDAQ: KMDA) will release its fiscal year and fourth quarter 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open. Management will host an investor conference call at 8:30am Eastern Time the same day and will webcast the discussion live.
Investors may join by phone (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) using conference ID 13758519 or via the live webcast link provided by the company.
Kamada (NASDAQ: KMDA) provided 2026 annual guidance of $200–$205 million in revenues and $50–$53 million of adjusted EBITDA, representing a midpoint increase of 13% revenue and 23% adjusted EBITDA versus the midpoint of its 2025 guidance. The company affirmed 2025 guidance of $178–$182 million in revenues and $40–$44 million of adjusted EBITDA and expects ~$75 million of year-end cash for 2025. 2026 guidance is based solely on continued organic growth across Proprietary and Distribution segments, with growth drivers cited as U.S. sales expansion, higher ex-U.S. sales of KAMRAB, GLASSIA, HEPAGAM and VARIZIG, Distribution launches in Israel and MENA, and increased plasma collection in Texas.
Kamada (NASDAQ: KMDA) was awarded a two-year extension by Canadian Blood Services to supply four specialty plasma-derived products (WINRHO, HEPAGAM, CYTOGAM, VARIZIG) from Q2-2026 to Q1-2028. The award is valued at $10–$14 million, securing approximately $5.0–$7.0 million of annual sales during that period. All four products are approved by Health Canada and the FDA. Kamada reiterated its 2025 revenue guidance of $178–$182 million and adjusted EBITDA guidance of $40–$44 million, and projected double-digit revenue and profitability growth for 2026 with detailed guidance due in January 2026.
Kamada (NASDAQ: KMDA) announced it will discontinue its Phase 3 InnovAATe trial of inhaled AAT after a prespecified interim futility analysis found the study is unlikely to meet its primary endpoint of lung function (FEV1).
The company said the decision is efficacy‑related and not due to safety concerns, and it will continue supplying GLASSIA (AAT-IV) internationally, including the U.S. and Canada via its licensee TAKEDA. Kamada reiterated its 2025 revenue guidance of $178M–$182M and adjusted EBITDA guidance of $40M–$44M, and projected double-digit revenue and profitability growth in 2026, with detailed guidance to follow in January 2026. Management will host a conference call today at 8:30am ET.
Kamada (NASDAQ: KMDA) reported strong Q3 and nine-month 2025 results, with Q3 revenue $47.0M (+13% YoY) and Q3 adjusted EBITDA $11.7M (+34% YoY). Nine-month revenue was $135.8M (+11% YoY) with adjusted EBITDA of $34.2M (+35% YoY). The company generated $17.9M cash from operations in the first nine months and held $72.0M cash as of Sep 30, 2025. Kamada reiterated full-year 2025 guidance of $178M–$182M revenue and $40M–$44M adjusted EBITDA. Key operational updates: FDA approval for Houston plasma center, launch of the SHIELD CYTOGAM investigator study, and an interim futility analysis for the InnovAATe Phase 3 trial due this quarter.
Kamada (NASDAQ: KMDA) announced on November 4, 2025 that the first patient was enrolled in an investigator-initiated, post-marketing randomized controlled multicenter trial named SHIELD testing CYTOGAM (Cytomegalovirus Immune Globulin Intravenous) to prevent late CMV disease in high-risk kidney transplant recipients (donor CMV seropositive / recipient seronegative).
The study will evaluate CYTOGAM dosed at the end of standard antiviral prophylaxis to reduce clinically significant late CMV; it is led by Camille Kotton, M.D., and David Wojciechowski, D.O. The release notes that up to one third of kidney transplant patients may develop late CMV after stopping prophylaxis.